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Abstract
Background: ALPPS (associating liver partition and portal vein ligation for staged hepatectomy) is a novel two-
stage strategy to induce rapid hypertrophy of the future liver remnant (FLR) when patients are in danger of postoperative
liver failure due to insufficient FLR. However, the effects of ALPPS on colorectal liver metastases (CRLM) are not clear so far.
The aim of our study was to determine whether ALPPS induces proliferation, apoptosis, or vascularization compared to
standard (one-stage) liver resection.
Methods: Six patients who underwent ALPPS were matched with 12 patients undergoing standard liver resection
regarding characteristics of the metastases (size, number), time of appearance (syn-/metachronous), preoperative
chemotherapy, primary tumor (localization, TNM stage, grading), and patient variables (gender, age). The largest resected
metastasis was used for the analyses. Tissue was stained for tumor cell proliferation (Ki67), apoptosis (TUNEL, caspase-3),
vascularization (CD31), and pericytes (αSMA).
Results: Vascularization (CD31; p = 0.149), proliferation (Mib-1; p = 0.244), and αSMA expression (p = 0.205) did not
significantly differ between the two groups, although a trend towards less proliferation and αSMA expression
was observed in patients undergoing ALPPS. Concerning apoptosis, caspase-3 staining showed significantly fewer
apoptotic cells upon ALPPS (p < 0.0001), but this was not confirmed by TUNEL staining (p = 0.7344).
Conclusions: ALPPS does not induce proliferation, apoptosis, or vascularization of CRLM when compared to standard
liver resection.
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Background
In colorectal liver metastases (CRLM) and primary liver
cancer, surgery offers the only chance for cure [1–4].
Nonetheless, 70 to 80% of patients suffering from CRLM
are regarded to be irresectable upon presentation. How-
ever, the terms “resectability” and “irresectability” in liver
surgery are not well defined, although several attempts
have been made to do this over the last decades [5–7].
One of the major problems that limit especially extended
liver surgery is the postoperatively remaining liver vol-
ume, also named future liver remnant (FLR). So far, ap-
proximately 20–25% of well-perfused normal tissue is
regarded to be sufficient to maintain the postoperative
liver function in otherwise healthy livers [8, 9]. Another
option to calculate the needed FLR is to refer the vol-
ume of the FLR to the body weight (BW). A FLR/BW
ratio of more than 0.5 is suggested to be enough to pre-
vent posthepatectomy liver failure (PHLF) [10].
To address the issue of small FLR, several strategies to
increase the remaining liver have been developed over
the last years. In particular, two-stage hepatectomy
(TSH) with or without interstage chemotherapy, as well
as portal vein embolization (PVE) of the contralateral
lobe, is currently in use [11–13]. Waiting time between
the two procedures is 8–12 weeks and 4–6 weeks after
TSH and PVE, respectively [14]. Although significant
improvement of resectability has been achieved with
these techniques, a number of patients remain irresect-
able either because of an inappropriate increase in FLR
or because of tumor progression during the waiting
period until resection [13, 15, 16]. We have recently in-
troduced a novel two-stage approach for rapid hyper-
trophy of the FLR in extended right hepatectomy by
combining a complete transection of the liver along the
falciforme ligament with dissection of the right portal
vein, known as ALPPS (associating liver partition and
portal vein ligation for staged hepatectomy) or “in situ
split liver resection” (ISS) [17]. After a median of 9 days,
an increase in FLR (Seg. II/III) of 86% was observed,
allowing rapid resection of the tumor-bearing liver lobe
[18]. Moreover, the feasibility rate, indicating the num-
ber of patients that were scheduled for ALPPS and com-
pleted the procedure, was reported to be between 97
and 100% [18, 19]. Taken together, ALPPS is the method
with the most effective and fastest increase of FLR asso-
ciated with the highest feasibility rate to complete the
strategy which is currently available.
The obvious fear associated with strategies for increas-
ing the FLR in patients with CRLM is the induction of
tumor growth and enhancement of metastatic spread
during the waiting period. DeGraaf and coworkers sug-
gested three mechanisms that might enhance tumor
growth upon PVE: induction of cytokine/growth factor
secretion, changes of hepatic blood flow (arterialization),
and a modified cellular host response [20]. Data con-
cerning the impact of PVE on tumor proliferation and
subsequently on overall (OS) and disease-free survival
(DFS) are controversial [13, 16, 21–24]. Regarding
ALPPS, almost no data are available about its effects on
the tumor. Only Tanaka and coworkers compared
patients with TSH/PVE and ALPPS regarding Ki67 ex-
pression index in the tumor (at first and second stages)
showing a significant induction of Ki67 in TSH/PVE but
not in ALPPS [25]. In contrast, Fukami described an in-
crease in Ki67 labeling index in a single patient after
ALPPS [26]. The aim of our study was to compare pa-
tients that underwent standard liver resection (one-
stage) with those that underwent ALPPS regarding
changes in tumor cell proliferation, apoptosis, and
vascularization.
Methods
Patients undergoing ALPPS (n = 6) were 1:2 matched with
patients after standard (one-stage) liver resection. One
matched patient after standard liver resection had to be
excluded from further analyses since no tumor material
was available for this study. Therefore, only 11 patients
after standard liver resection were included into the ana-
lyses. Matching was performed regarding size, number
(both based on the postoperative pathologic reports), and
timing of appearance of the metastases (syn-/metachro-
nous), preoperative chemotherapy, localization, TNM
stage, and grading of the primary tumor, as well as patient
characteristics (age, gender). In case of neoadjuvant ther-
apy, size of the biggest lesion was measured at the time of
initial staging before chemotherapy and upon re-staging
just before resection from CT scans. To determine
changes in the size of the lesions during ALPPS proced-
ure, size of the biggest metastasis was determined from
CT scans just before the first and prior to the second
stage. All patients underwent resection at the Department
of Surgery, University Hospital Regensburg between 2006
and 2011. Informed consent was obtained from all pa-
tients prior to surgery. Data were collected retrospectively.
The study was approved by the local IRB at the University
Hospital Regensburg (No. 15-101-0039).
Histological analysis
The largest resected metastasis based on the postop-
erative pathological report of ALPPS group was com-
pared to the largest in the standard liver resection
group. Tissue samples of CRLM were fixed in forma-
lin and paraffin embedded prior to cutting them at
3 μm. SuperFrost Plus slides (Thermo Scientific,
Massachusetts, USA) were used to perform immuno-
histochemistry and TUNEL staining.
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Immunhistochemistry
The Roche Ventana BenchMark Ultra staining system
and the ultraView DAB detection kit were used for all
immunostainings. After warming the slides up to 75 °C,
deparaffinizing and pretreating them (not for αSMA),
the staining kit was applied. Having added 3% H2O2, the
slides were incubated with the primary antibody. To
visualize the bound structures, the secondary antibody,
diaminobenzidine (DAB), H2O2, and copper were ap-
plied. Having counterstained the sections and washed
them twice, they were dehydrated through increasing al-
cohol concentration and covered with Entellan® (Merck
Millipore, Darmstadt, Germany).
Tumor specimens were stained for Mib-1/Ki67 (prolif-
eration, mouse anti-human monoclonal Ki67 antibody,
DAKO, 1:100), cleaved caspase-3 (apoptosis, rabbit
polyclonal antibody, Cell Signaling, 1:100), CD31
(vascularization, mouse anti-human monoclonal anti-
body, DAKO, 1:20), and αSMA (smooth muscle actin,
pericytes, mouse anti-human monoclonal, Chemicon,
1:500). Measurements of the tumor slide were per-
formed in four random fields at ×40 magnification at the
tumor invasive front. Ki67-positive and caspase-3-
positive tumor cells were counted per high-power field
(hpf ), and averages were calculated. CD31-positive
stained vessels and αSMA-positive areas were measured
using ImageJ software and expressed as pixels per hpf.
TUNEL assay
To detect DNA fragmentation and consequently
apoptotic cells in tumor specimens, terminal deoxy-
nucleotidyl transferase-mediated dUTP nick end la-
beling assay (TUNEL; DeadEnd™ Colorimetric Tunel
System, Promega) was used according to the manu-
facturer’s instructions. In brief, formalin-fixed and
paraffin-embedded slides (3 μm) were deparaffinized
by Xylol, hydrogenated through a graded ethanol
series, 0.85% NaCl, and PBS buffer, and fixed with
4% paraformaldehyde. After covering the tissues with
protein kinase K, they were incubated with the reac-
tion mixture containing terminal deoxynucleotidyl
transferase, equilibration buffer, and biotinylated nu-
cleotide mix for 1 h at 37 °C to label 3 OH DNA
ends. Streptavidin- and DAB-bound biotin was quan-
tified, and nuclei were stained dark brown. Slides
were counterstained with hemalaun (Merck Milli-
pore, Darmstadt, Germany) and covered with aqua-
tex (Merck Millipore, Darmstadt, Germany). DNA
fragmentation was detected by selecting four fields
at ×40 magnification in each tumor section at the
invasive front and counting positive stained nuclei.
Data were expressed as the number of apoptotic
cells per high-power field.
Statistical analyses
To assess any significance between both groups,
Student’s t test and Fisher’s exact test were used. For both
tests, a p value <0.05 was considered to be statistically sig-
nificant. Results were expressed as the mean ±SD.
Results
Characteristics of the six patients with ALPPS and 11
patients with standard liver resection regarding primary
tumors and liver metastases are summarized in Table 1.
No significant difference was observed between both
groups. Patients without preoperative therapy underwent
liver resection within 2–3 weeks after diagnosis. In case
of neoadjuvant therapy (n = 6 patients), liver resection
was performed 4–6 months after the initial diagnosis.
All patients in the ALPPS group underwent extended
right hepatectomy (+/− Seg. I, n = 3 each). Median time
between step 1 and step 2 was 10 days (range 8–12).
Based on the CT scans, the size of the largest lesion
before the first step of ALPPS was 6.22 cm (±1.30)
and before the second step of ALPPS was 6.43
(±1.41) (p = 0.793). Standard liver resection included
six patients with multiple atypical resections, one
right and one left hemihepatectomy, one left hemihe-
patectomy with atypical resection on the right side,
and two extended right hepatectomies.
Tumor cell proliferation
Tumor cell proliferation was determined by Ki67 stain-
ing. Results showed a lower number of Ki67-positive
tumor cells in the ALPPS group (46.08 ± 19.88 cells/hpf )
than after standard liver resection (74.73 ± 13.89 cells/
hpf; Fig. 1). However, this did not reach statistical signifi-
cance (p = 0.244).
Apoptosis
Caspase-3 staining revealed significantly fewer apoptotic
cells after ALPPS than after standard liver resection
(11.73 ± 1 cells/hpf vs. 4.19 ± 0.38 cells/hpf; p < 0.001;
Fig. 2). To confirm this finding, TUNEL staining was
performed. Although the number of TUNEL-positive
cells was also decreased upon ALPPS, results did not
show a significant difference between ALPPS and stand-
ard liver resection (5.52 ± 1.94 cells/hpf vs. 6.6 ± 2.04
cells/hpf; p = 0.734; Fig. 3).
Vascularization
Vascularization was determined by a CD31 vessel area.
Results showed no significant difference between the
ALPPS group (239.46 ± 4.08 pixels/hpf ) compared to pa-
tients that underwent standard liver resection (244.43 ±
1.16 pixels/hpf; p = 0.149; Fig. 4). Since pericytes have
been implicated in tumor growth and vascularization,
αSMA was assessed. Again, no significant difference
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Table 1 Characteristics of patients, primary tumors, and metastases
ALPPS (n = 6) Standard liver resection (n = 11) p value
Age 67.1 ± 3.48 64.1 ± 3.45 0.522
Male/female 4/2 5/6 0.620
T stage
1 0 0 1.0
2 1 1 1.0
3 3 7 0.644
4 2 3 1.0
N stage
0 3 4 0.644
1 2 3 1.0
2 1 4 0.6
Grading
1 0 0 1.0
2 4 8 1.0
3 2 3 1.0
Number of metastases 3.12 ± 1.28 2.56 ± 0.55 0.607
Size of metastases 6.80 ± 1.46 4.06 ± 0.55 0.126
Syn/meta 3/3 6/5 1.0
Preoperative chemotherapy 2 4 1.0
Tumor size at the time of diagnosis (before preoperative chemotherapy)a 4.90 ± 1.60 2.95 ± 1.20 0.161
Tumor size before resection (after preoperative chemotherapy)a 2.85 ± 0.15 2.35 ± 1.01 0.547
aBased on CT scan
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Fig. 1 Tumor cell proliferation in ALPPS vs. standard liver resection.
a No significant difference was found regarding Ki67-positive cells.
b Examples for Ki67 staining in ALPPS (left side) and standard liver
resection (right side)
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Fig. 2 Caspase-3 staining in ALPPS vs. standard liver resection. a
Significantly less caspase-3-positive cells were detected after ALPPS
(*p < 0.001). b Examples for caspase-3 staining in ALPPS (left side) and
standard liver resection (right side)
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between ALPPS and standard liver resection was
found (7.65 ± 1.15 pixels/hpf vs. 10.75 ± 1.6 pixels/hpf;
p = 0.205; Fig. 5).
Discussion
The present study provides evidence that ALPPS is not
associated with parameters characteristic of increased
tumor growth at the time point of final resection of me-
tastases. Results show no appreciable difference in
tumor cell proliferation (Ki67), apoptosis (TUNEL),
vascularization (CD31), or pericyte coverage (αSMA)
when ALPPS specimens were compared to standard
liver resection.
Several strategies to increase the FLR in patients with
advanced CRLM or primary liver cancer are in use. Most
frequently, PVE of the contralateral liver lobe is per-
formed. The effects of strategies to increase the FLR on
tumor cell proliferation have been addressed in several
studies. Animal experiments suggest that partial hepa-
tectomy increases the growth of colorectal liver metasta-
ses in liver remnants [27]. With regard to portal vein
occlusion, a rat model by Maggiori et al. showed that
the tumor volume in the embolized liver lobe was
smaller compared to non-embolized controls, whereas
the opposite effect was observed on the contralateral
side [28]. In contrast, Hoekstra et al. found an increase
in tumor growth rate in the embolized liver lobe after
portal vein occlusion in a rabbit model [29]. The same
group confirmed the latter findings in a clinical setting
T
U
N
E
L-
po
si
tiv
e 
ce
lls
/h
pf
0
2
4
6
8
10
ALPPS standard liver
resection
ALPPS standard liver resection
Fig. 3 TUNEL-positive cells in ALPPS vs. standard liver resection. a
No significant difference was found regarding TUNEL-positive cells.
b Examples for TUNEL staining in ALPPS (left side) and standard liver
resection (right side)
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Fig. 4 CD31 vessel area in ALPPS vs. standard liver resection. a No
significant difference was found regarding CD31 vessel area. b Examples
for CD31 staining in ALPPS (left side) and standard liver resection
(right side)
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Fig. 5 αSMA positive area in ALPPS vs. standard liver resection. a No
significant difference was found regarding αSMA positive area.
b Examples for αSMA staining in ALPPS (left side) and standard
liver resection (right side)
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when comparing 28 patients after PVE with 30 patients
without preoperative PVE [22]. Pamecha and coworkers
showed a higher mitotic rate and a significant increase
in Ki67 proliferation index after PVE, but no differences
regarding necrosis or apoptosis when comparing sam-
ples from patients with preoperative PVE to those with-
out PVE [30]. With regard to ALPPS, an increase in
Ki67 labeling index from 60 to 80% between step 1 and
step 2 of the procedure was reported in a single patient
with CRLM [26]. Very recently, Tanaka et al. compared
10 patients after ALPPS with 47 patients after “classical”
two-stage hepatectomy, including PVE/PVL. Results
show no difference in Ki67 expression between both
groups after the first step, but higher Ki67 expression
was observed after the second operation with the
classical two-stage procedure [25]. Findings from our
present study go along with those of Tanaka and co-
workers, since we did not detect any difference between
ALPPS and standard liver resection with regard to Ki67
expression, although our control group (standard (one-
stage) liver resection) is different. Moreover, we did not
detect a difference regarding apoptosis in our study
upon ALPPS which is similar to the results from
Pamecha et al. upon PVE [30]. Finally, we determined
the effects of ALPPS on metastases vascularization
(CD31) and pericyte coverage (αSMA). To our know-
ledge, this is the first time that this was addressed in this
setting. Nonetheless, the issue of vascularization is of
particular importance since Schadde et al. very recently
described an increase of local hypoxia and a consecutive
increase in HIF-1α (hypoxia-inducible factor-1α) expres-
sion in an experimental rat model after ALPPS [31].
Since the hypoxia-driven increase in HIF-1α is the main
stimulus for VEGF-A (vascular endothelial growth
factor-A)-induced angiogenesis, one might have ex-
pected an effect on vascularization. However, neither re-
garding vascularization (CD31) nor regarding pericyte
coverage (αSMA) a difference was detectable. Taken to-
gether, our results indicate that ALPPS does not have a
significant impact on the tumor itself.
The obvious fear is that strategies increasing growth of
the liver remnant might negatively impact on OS or
DFS. With regard to PVE, clinical data on long-term
survival is controversial. A study by Hoekstra et al. re-
ported 3-year overall survival of 26% after PVE versus
77% without preoperative embolization [22]. In contrast,
Ardito and coworkers found no difference in OS, DFS,
or liver-specific DFS when comparing 20 patients after
PVE with the same number of patients without PVE be-
fore right or extended right hepatectomy [21]. Moreover,
a study by Simoneau et al. showed no difference regard-
ing OS even upon tumor progression after PVE. How-
ever, patients with tumor progression had significantly
shorter DFS [23]. Recently, a systematic review and
meta-analysis by Giglio and coworkers concluded that
PVE has no negative impact on hepatic recurrence and
OS [32]. With respect to ALPPS, data are even more
limited. Oldhafer and colleagues reported early recur-
rence after a median of 8 months in six of seven patients
that underwent ALPPS for CRLM [33]. We have re-
cently published data from our experience showing a
median DFS of 18.7 months and 3-year OS of 64% after
ALPPS for CRLM [18]. Schadde et al. reported 1- and 2-
year DFS of 59 and 41%, respectively, with a median
DFS of 14 months from the ALPPS registry [34]; 1- and
2-year OS in this study was 76 and 62%, respectively.
Finally, Alvarez et al. reported a DFS of 67% after 1 year
and 40% after 2 years, although only 19 of 30 patients in
this study suffered from CRLM [35]. The high and early
recurrence rates after ALPPS compared to PVE might
be explained by the fact that a significant number of pa-
tients after PVE do not undergo liver resection due to
disease progression or insufficient growth of the liver
remnant [36]. Therefore, PVE is sometimes considered to
be a better selection method for patients undergoing ex-
tensive liver resection for CRLM. However, one has to
keep in mind that even after standard liver resection with
curative intent, recurrence rates up to 70% have been re-
ported [37]. In summary, much more data is available
concerning long-term OS and DFS after PVE than after
ALPPS for CRLM, but the impact of both procedures on
oncologic survival recurrence is still not clear so far.
Our study harbors some limitations. First, the number
of patients included is limited. One reason for that is the
novelty of the ALPPS approach with limited patients being
treated in this way to date. Second, the control group of
our population is very heterogeneous. Optimal control for
assessing effects of ALPPS on tumor cells would have
been a biopsy from the metastases upon the first stage of
the procedure. However, to avoid any harm to the patient,
e.g., by biopsy-driven tumor spread, we did not do this.
Third, we could not provide data on long-term OS and
DFS. This owes to the fact that one of the six patients in
the ALPPS group died in the early postoperative phase,
and therefore, oncologic survival analyses were not rea-
sonable. The latter even shows that ALPPS is a procedure
with relevant morbidity and mortality that should only be
performed in patients with advanced liver metastases that
are otherwise not eligible for surgery.
Conclusions
The results of our study showed no difference regarding
proliferation, apoptosis, and vascularization in CRLM
when comparing matched patients that underwent
ALPPS with those that underwent standard (one-step)
liver resection. The study, therefore, increases the body
of evidence for the use of ALPPS in selected patients
with otherwise unresectable CRLM.
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